{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:22:33Z","timestamp":1790889753171,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,24]]},"DOI":"10.7759\/cureus.47608","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T03:51:37Z","timestamp":1698205897000},"source":"Crossref","is-referenced-by-count":18,"title":["Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ernesto","family":"Calderon Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saruveish","family":"Mogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha Altaf","family":"Jangda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyaba J","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palvi","family":"Mroke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Sajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash R","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22020191","article-title":"Silymarin\/silybin and chronic liver disease: a marriage of many years","volume":"22","author":"Federico A","year":"2017","unstructured":"Federico A, Dallio M, Loguercio C. Silymarin\/silybin and chronic liver disease: a marriage of many years. Molecules. 2017, 22:191. 10.3390\/molecules22020191","journal-title":"Molecules"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221683","article-title":"Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial","volume":"14","author":"Navarro VJ","year":"2019","unstructured":"Navarro VJ, Belle SH, D'Amato M, et al.. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial. PLoS One. 2019, 14:e0221683. 10.1371\/journal.pone.0221683","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165327","article-title":"Mechanistic insights into the pharmacological significance of silymarin","volume":"27","author":"Wadhwa K","year":"2022","unstructured":"Wadhwa K, Pahwa R, Kumar M, et al.. Mechanistic insights into the pharmacological significance of silymarin. Molecules. 2022, 27:5327. 10.3390\/molecules27165327","journal-title":"Molecules"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.8265","article-title":"Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial","volume":"308","author":"Fried MW","year":"2012","unstructured":"Fried MW, Navarro VJ, Afdhal N, et al.. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012, 308:274-82. 10.1001\/jama.2012.8265","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115070-00005","article-title":"Silymarin: a review of its clinical properties in the management of hepatic disorders","volume":"15","author":"Wellington K","year":"2001","unstructured":"Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs. 2001, 15:465-89. 10.2165\/00063030-200115070-00005","journal-title":"BioDrugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-016-0239-9","article-title":"A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients","volume":"10","author":"Paziewska A","year":"2017","unstructured":"Paziewska A, Habior A, Rogowska A, et al.. A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. BMC Med Genomics. 2017, 10:2. 10.1186\/s12920-016-0239-9","journal-title":"BMC Med Genomics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2515690X211068826","article-title":"Role of silymarin in cancer treatment: facts, hypotheses, and questions","volume":"27","author":"Koltai T","year":"2022","unstructured":"Koltai T, Fliegel L. Role of silymarin in cancer treatment: facts, hypotheses, and questions. J Evid Based Integr Med. 2022, 27:2515690X211068826. 10.1177\/2515690X211068826","journal-title":"J Evid Based Integr Med"},{"key":"ref8","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","year":"2021","unstructured":"The PRISMA 2020 statement. an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71.","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref11","article-title":"","year":"2019","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed). John Wiley & Sons, Chichester (UK); 2019. https:\/\/training.cochrane.org\/handbook."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2020.1797104","article-title":"Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes","volume":"129","author":"Ghalandari K","year":"2020","unstructured":"Ghalandari K, Shabani M, Khajehlandi A, Mohammadi A. Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes. Arch Physiol Biochem. 2020, 129:76-81. 10.1080\/13813455.2020.1797104","journal-title":"Arch Physiol Biochem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-32","article-title":"Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial","volume":"12","author":"Yakoot M","year":"2012","unstructured":"Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterol. 2012, 12:32. 10.1186\/1471-230X-12-32","journal-title":"BMC Gastroenterol"},{"key":"ref14","article-title":"Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study","volume":"19","author":"Aller R","year":"2015","unstructured":"Aller R, Izaola O, G\u00f3mez S, et al.. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015, 19:3118-24.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000017117","article-title":"Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease","volume":"10","author":"Allain H","year":"1999","unstructured":"Allain H, Sch\u00fcck S, Lebreton S, Strenge-Hesse A, Braun W, Gandon JM, Brissot P. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1999, 10:181-5. 10.1159\/000017117","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.18663","article-title":"Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"32","author":"Angulo P","year":"2000","unstructured":"Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000, 32:897-900. 10.1053\/jhep.2000.18663","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-0052-6","article-title":"Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study","volume":"53","author":"Angulo P","year":"2008","unstructured":"Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci. 2008, 53:1716-20. 10.1007\/s10620-007-0052-6","journal-title":"Dig Dis Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2021.107067","article-title":"The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial","volume":"7","author":"Mirzaei E","year":"2021","unstructured":"Mirzaei E, Sabetian G, Masjedi M, Heidari R, Mirjalili M, Dehghanian A, Vazin A. The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial. Clin Exp Hepatol. 2021, 7:149-55. 10.5114\/ceh.2021.107067","journal-title":"Clin Exp Hepatol"},{"key":"ref19","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial","volume":"5","author":"Solhi H","year":"2014","unstructured":"Solhi H, Ghahremani R, Kazemifar AM, Hoseini Yazdi Z. Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial. Caspian J Intern Med. 2014, 5:9-12.","journal-title":"Caspian J Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.19082\/5098","article-title":"The impact of silymarin on improvement of hepatic abnormalities in patients with severe preeclampsia: a randomized clinical trial","volume":"9","author":"Baghbahadorani FK","year":"2017","unstructured":"Baghbahadorani FK, Miraj S. The impact of silymarin on improvement of hepatic abnormalities in patients with severe preeclampsia: a randomized clinical trial. Electron Physician. 2017, 9:5098-106. 10.19082\/5098","journal-title":"Electron Physician"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1089938","article-title":"Novel nutraceutical supplements with yeast \u03b2-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: a double-blind randomized trial","volume":"13","author":"Nehmi-Filho V","year":"2022","unstructured":"Nehmi-Filho V, Santamarina AB, de Freitas JA, et al.. Novel nutraceutical supplements with yeast \u03b2-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: a double-blind randomized trial. Front Endocrinol (Lausanne). 2022, 13:1089938. 10.3389\/fendo.2022.1089938","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00681.x","article-title":"Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial","volume":"23","author":"Gharagozloo M","year":"2009","unstructured":"Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol. 2009, 23:359-65. 10.1111\/j.1472-8206.2009.00681.x","journal-title":"Fundam Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04138.x","article-title":"Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C","volume":"21","author":"Gordon A","year":"2006","unstructured":"Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006, 21:275-80. 10.1111\/j.1440-1746.2006.04138.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.6099","article-title":"Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study","volume":"12","author":"Hajiaghamohammadi AA","year":"2012","unstructured":"Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study. Hepat Mon. 2012, 12:e6099. 10.5812\/hepatmon.6099","journal-title":"Hepat Mon"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22800","article-title":"Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing-remitting multiple sclerosis: a clinical trial study","volume":"35","author":"Ghiasian M","year":"2021","unstructured":"Ghiasian M, Nafisi H, Ranjbar A, Mohammadi Y, Ataei S. Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing-remitting multiple sclerosis: a clinical trial study. J Biochem Mol Toxicol. 2021, 35:e22800. 10.1002\/jbt.22800","journal-title":"J Biochem Mol Toxicol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_929_19","article-title":"Investigating the impact of silymarin on liver oxidative injury","volume":"9","author":"Jamalian M","year":"2020","unstructured":"Jamalian M, Mahmodiyeh B, Saveiee S, Solhi H. Investigating the impact of silymarin on liver oxidative injury. J Family Med Prim Care. 2020, 9:1707-11. 10.4103\/jfmpc.jfmpc_929_19","journal-title":"J Family Med Prim Care"},{"key":"ref27","article-title":"Effects of silybum marianum on patients with chronic hepatitis C","volume":"16","author":"Kalantari H","year":"2011","unstructured":"Kalantari H, Shahshahan Z, Hejazi SM, Ghafghazi T, Sebghatolahi V. Effects of silybum marianum on patients with chronic hepatitis C. J Res Med Sci. 2011, 16:287-90.","journal-title":"J Res Med Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9703-2","article-title":"The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study","volume":"52","author":"Loguercio C","year":"2007","unstructured":"Loguercio C, Federico A, Trappoliere M, et al.. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007, 52:2387-95. 10.1007\/s10620-006-9703-2","journal-title":"Dig Dis Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2022.100190","article-title":"Effect of 8\u00a0weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery","volume":"14","author":"Mirhashemi SH","year":"2022","unstructured":"Mirhashemi SH, Hakakzadeh A, Yeganeh FE, Oshidari B, Rezaee SP. Effect of 8\u00a0weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery. Metabol Open. 2022, 14:100190. 10.1016\/j.metop.2022.100190","journal-title":"Metabol Open"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56100544","article-title":"Silymarin in combination with vitamin c, vitamin e, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients","volume":"56","author":"Curcio A","year":"2020","unstructured":"Curcio A, Romano A, Cuozzo S, et al.. Silymarin in combination with vitamin c, vitamin e, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients. Medicina (Kaunas). 2020, 56:544. 10.3390\/medicina56100544","journal-title":"Medicina (Kaunas)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13236","article-title":"The effect of silymarin on liver enzymes in patients taking isotretinoin: a randomized clinical trial","volume":"33","author":"Mirnezami M","year":"2020","unstructured":"Mirnezami M, Jafarimanesh H, Rezagholizamenjany M, Alimoradian A, Ranjbaran M. The effect of silymarin on liver enzymes in patients taking isotretinoin: a randomized clinical trial. Dermatol Ther. 2020, 33:e13236. 10.1111\/dth.13236","journal-title":"Dermatol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2009.02.002","article-title":"A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis","volume":"16","author":"El-Kamary SS","year":"2009","unstructured":"El-Kamary SS, Shardell MD, Abdel-Hamid M, et al.. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009, 16:391-400. 10.1016\/j.phymed.2009.02.002","journal-title":"Phytomedicine"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04503.x","article-title":"Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial","volume":"33","author":"Freedman ND","year":"2011","unstructured":"Freedman ND, Curto TM, Morishima C, et al.. Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Aliment Pharmacol Ther. 2011, 33:127-37. 10.1111\/j.1365-2036.2010.04503.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9199190","article-title":"Effect of silymarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis C patients: a miniature clinical trial","volume":"2022","author":"Ahmed S","year":"2022","unstructured":"Ahmed S, Ullah N, Parveen S, et al.. Effect of silymarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis C patients: a miniature clinical trial. Oxid Med Cell Longev. 2022, 2022:9199190. 10.1155\/2022\/9199190","journal-title":"Oxid Med Cell Longev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7537","article-title":"Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19: A double-blind placebo-controlled clinical trial","volume":"36","author":"Aryan H","year":"2022","unstructured":"Aryan H, Farahani RH, Chamanara M, et al.. Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19: A double-blind placebo-controlled clinical trial. Phytother Res. 2022, 36:3924-31. 10.1002\/ptr.7537","journal-title":"Phytother Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2004.06.015","article-title":"Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results","volume":"36","author":"Tanamly MD","year":"2004","unstructured":"Tanamly MD, Tadros F, Labeeb S, et al.. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004, 36:752-9. 10.1016\/j.dld.2004.06.015","journal-title":"Dig Liver Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v5.i3.109","article-title":"Silymarin in non alcoholic fatty liver disease","volume":"5","author":"Cacciapuoti F","year":"2013","unstructured":"Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol. 2013, 5:109-13. 10.4254\/wjh.v5.i3.109","journal-title":"World J Hepatol"},{"key":"ref38","article-title":"A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease","volume":"9","author":"Hashemi S","year":"2009","unstructured":"Hashemi S, Hajiani E, Sardabi E. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon. 2009, 9:265-70.","journal-title":"Hepat Mon"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/BF02836467","article-title":"The state of insulin resistance in patients with nonalcoholic fatty liver and the intervention with Gankangyin","volume":"11","author":"Deng YQ","year":"2005","unstructured":"Deng YQ, Fan XF, Li JP. The state of insulin resistance in patients with nonalcoholic fatty liver and the intervention with Gankangyin. Chin J Integr Med. 2005, 11:117-22. 10.1007\/BF02836467","journal-title":"Chin J Integr Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2023-1-4","article-title":"Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report","volume":"12","author":"Franklin H","year":"2023","unstructured":"Franklin H. Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report. Drugs Context. 2023, 12:2023-1-4. 10.7573\/dic.2023-1-4","journal-title":"Drugs Context"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01251-y","article-title":"Silymarin as supportive treatment in liver diseases: a narrative review","volume":"37","author":"Gillessen A","year":"2020","unstructured":"Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020, 37:1279-301. 10.1007\/s12325-020-01251-y","journal-title":"Adv Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/jsfa.9115","article-title":"Effects of silymarin on metabolic syndrome: a review","volume":"98","author":"Vahabzadeh M","year":"2018","unstructured":"Vahabzadeh M, Amiri N, Karimi G. Effects of silymarin on metabolic syndrome: a review. J Sci Food Agric. 2018, 98:4816-23. 10.1002\/jsfa.9115","journal-title":"J Sci Food Agric"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13856","article-title":"The Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 2: management and special groups","volume":"33","author":"Chitturi S","year":"2018","unstructured":"Chitturi S, Wong VW, Chan WK, et al.. The Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 2: management and special groups. J Gastroenterol Hepatol. 2018, 33:86-98. 10.1111\/jgh.13856","journal-title":"J Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/941085","article-title":"Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials","volume":"2014","author":"Yang Z","year":"2014","unstructured":"Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014, 2014:941085. 10.1155\/2014\/941085","journal-title":"Biomed Res Int"},{"key":"ref45","article-title":"","author":"van Wyk BE","year":"2004","unstructured":"van Wyk BE, Wink M. Medicinal Plants of the World: An Illustrated Scientific Guide to Important Medicinal Plants and Their Uses. Timber Press, Portland; 2004. https:\/\/books.google.com\/books\/about\/Medicinal_Plants_of_the_World.html?id=bTdoTayyVrEC."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/195494-impact-of-silymarin-supplements-on-liver-enzyme-levels-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:11Z","timestamp":1707509291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/195494-impact-of-silymarin-supplements-on-liver-enzyme-levels-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.47608","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}